Suzuken Co stock analysis
Suzuken Co (SZUKF) Stock Price & Analysis
SZUKF Stock Chart & Stats
- Day’s Range
- $16.92 - $18.24
- 52-Week Range
- $13.69 - $22.65
- Previous Close
- $17.94
- Volume
- N/A
- Average Volume (3M)
- 420
- Market Cap
- $2.29B
- Enterprise Value
- $209.64B
- Total Cash (Recent Filing)
- $148.78B
- Total Debt (Recent Filing)
- $24.38B
- Price to Earnings (P/E)
- 10.5
- Beta
- 0.01
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- 0.32
- Next Dividend Ex-Date
- Mar 30, 2027
- Dividend Yield
- 3.39%
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
A debt-free balance sheet gives Suzuken substantial financial flexibility and reduces interest and refinancing pressure. The stable equity base can support investment, dividends, and resilience through operating volatility, strengthening the company’s ability to manage its healthcare distribution franchise over the next several quarters.
Steady Revenue Growth
Steady revenue expansion indicates that Suzuken continues to grow sales across its pharmaceutical and healthcare distribution activities. Even moderate growth can compound over time in a large operating network, supporting scale, customer retention, and continued funding for logistics and related services.
Improved Profitability
Improved profitability and strong recent EPS growth show better earnings power than earlier in the period. If maintained, this progress can increase internally generated capital, strengthen returns on the stable equity base, and provide greater capacity to invest while supporting shareholder distributions.
Bears Say
Thin Operating Margins
Thin margins leave Suzuken with limited room to absorb higher operating costs, unfavorable product mix, or execution setbacks without affecting earnings. Because modest changes in expenses can have an outsized effect on profit, sustained margin improvement remains important to the durability of its earnings growth.
Volatile Cash Conversion
Uneven cash generation reduces confidence that accounting profits will consistently translate into available funds. The reported year-to-year swings suggest working-capital movements can materially affect liquidity, potentially complicating investment, dividend, and other capital-allocation decisions even with a conservative balance sheet.
Recent EBIT Pressure
A decline in EBIT while revenue increased indicates that recent sales growth has not fully converted into operating-profit growth. If cost pressure persists, it could offset the benefits of expanding revenue and improved net income, making future margin expansion and earnings progression less certain.
Suzuken Co News
SZUKF FAQ
What was Suzuken Co’s price range in the past 12 months?
What is Suzuken Co’s market cap?
When is Suzuken Co’s upcoming earnings report date?
How were Suzuken Co’s earnings last quarter?
Is Suzuken Co overvalued?
Does Suzuken Co pay dividends?
What is Suzuken Co’s EPS estimate?
How many shares outstanding does Suzuken Co have?
What happened to Suzuken Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Suzuken Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Suzuken Co
Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a wholesale distributor of pharmaceuticals, serving both domestic and international markets. The company's diverse activities are organized into four distinct divisions. Its Pharmaceutical Distribution Business focuses on sourcing a wide array of products, including ethical drugs, diagnostic reagents, medical devices, and other health-related items directly from manufacturers, and then supplying these to healthcare institutions and pharmacies. The Pharmaceutical Manufacturing Business is dedicated to the research, development, production, and commercialization of prescription pharmaceuticals and diagnostic tools, with a particular emphasis on diabetes and kidney-related conditions. Through its Pharmacy Business segment, Suzuken offers services via family pharmacists, works to enhance the efficiency of local pharmacy operations, and provides educational support. The Healthcare-Related Services Business encompasses a variety of support functions, such as contract distribution for manufacturers, the distribution of orphan drugs, and nursing care services. This segment is also involved in the development, manufacturing, and sale of medical equipment, including electrocardiographs, blood pressure monitors, stethoscopes, general medical supplies, and health promotion devices. Furthermore, Suzuken Co., Ltd. publishes medical journals for healthcare professionals and collaborates with Bushu Pharmaceuticals Ltd. to provide specialized contract drug services. The company was established in 1932 and is headquartered in Nagoya, Japan.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Shigeru Asano
- Employees
- 12,717
- Website
- www.suzuken.co.jp
- Address
- 8 Higashi Kataha-machi, Nagoya, AI, 461-8701, JP
Suzuken Co (SZUKF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 8 | 0 | 4 |









